Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $4.5 million.

  • ImmunityBio's Other Non-Current Assets rose 2278.34% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 2278.34%. This contributed to the annual value of $4.4 million for FY2024, which is 5447.92% up from last year.
  • ImmunityBio's Other Non-Current Assets amounted to $4.5 million in Q3 2025, which was up 2278.34% from $3.6 million recorded in Q2 2025.
  • ImmunityBio's Other Non-Current Assets' 5-year high stood at $7.4 million during Q3 2021, with a 5-year trough of $1.9 million in Q1 2021.
  • Moreover, its 5-year median value for Other Non-Current Assets was $4.5 million (2025), whereas its average is $4.5 million.
  • The largest annual percentage gain for ImmunityBio's Other Non-Current Assets in the last 5 years was 26678.17% (2021), contrasted with its biggest fall of 5297.46% (2021).
  • ImmunityBio's Other Non-Current Assets (Quarter) stood at $6.8 million in 2021, then fell by 28.27% to $4.9 million in 2022, then tumbled by 40.74% to $2.9 million in 2023, then soared by 54.48% to $4.4 million in 2024, then grew by 0.54% to $4.5 million in 2025.
  • Its Other Non-Current Assets was $4.5 million in Q3 2025, compared to $3.6 million in Q2 2025 and $4.5 million in Q1 2025.